
On Feb. 13, 2026, Henan Genuine Biotech Co., Ltd. announced that the clinical trial of self-developed anti-tumor drug GEN-725 tablets (Azvudine) in combination with PD-1 monoclonal antibody in the treatment of advanced solid tumors was approved by the National Medical Products Administration.

On January 21, 2026, Genuine Biotech officially announced that Mr. Gao Jun joined Genuine Biotech as Chief Financial Officer (CFO) to take charge of the Company's finance, capital operation, and compliance system improvement.